Clinical trials: Neuroendocrine Tumors, NET
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC)
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine…
- Trial name
- NCT04525638
- Testing
- 177Lu-Dotatate, Nivolumab
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Neuroendocrine Tumors, Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients…
- Trial name
- SYMNET (NCT01234168)
- Where
- 57 sites in Czechia, France and 6 more
- Volunteers
- 340 people
- Sponsor
- Ipsen
Neuroendocrine Tumors, Carcinoid Syndrome
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat…
- Conditions
- Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
- Trial name
- NET-PACS (NCT04713202)
- Testing
- Telotristat ethyl, Peptide Receptor Radionuclide Therapy
- Where
- United States
- Sponsor
- Chandrikha Chandrasekhara
Neural Crest Tumor, Neuroendocrine Tumors
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
The aim of this study is to evaluate the potential and feasibility of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neural crest and neuroendocrine tumors.
- Trial name
- NCT04258592
- Testing
- (18F)MFBG, PET/CT, Venous blood samples
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Neuroendocrine Tumors
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers
- Trial name
- NCT04622631
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Dr. Nayruz Knaana
Neuroendocrine Tumor
Optimal Feeding for NET Patients
This study aims to investigate if optimal personalized consultation by a dietician for a healthy diet focused on food which contains sufficient vitamins and minerals improves gastrointestinal symptoms as determined by an improved…
- Trial name
- DIVIT-pilot (NCT02481804)
- Testing
- Dietary intervention, Standard treatment
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Head Neck Tumors, Neuroendocrine Tumors
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In…
- Conditions
- Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer
- Trial name
- RaC-Ad (NCT04166006)
- Testing
- Autologous DC vaccine, Interleukin-2
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neuroendocrine Tumors, Carcinoid Tumor of GI System
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
Primary Objective: To assess how an amino acid based medical food (Enterade®) helps maintain the intestine's ability to absorb and retain fluids, leading to a reduction in diarrhea due to Neuroendocrine Tumors (NET) and/or…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor of GI System, Diarrhea, Carcinoid Syndrome
- Trial name
- NCT03722511
- Testing
- Amino Acid Based Medical Food/Drink
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lowell Anthony, MD
Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
This is a non-randomized phase II , open label, comparative study. Patients with advanced non-resectable and/or progressive gastro-entero-pancreatic Neuroendocrine Tumours - GEP-NET, (G1, G2 and G3), Broncho-pulmonary Carcinoids…
- Trial name
- POLNETS_PRRT (NCT04029428)
- Testing
- 90Y-DOTATATE, (177Lu-DOTAOTyr3)Octreotate, 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- University of Warmia and Mazury
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Neuroendocrine Tumors
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors.
- Trial name
- NCT01873248
- Testing
- 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jonsson Comprehensive Cancer Center
NET, Radionucleide Therapy
DCEUS to Assess Treatment Response to PRRT in GEP-NET
Neuroendocrine tumors (NETs) are a wide group of neoplasms arising from the diffuse neuroendocrine cell system that features significant molecular and biological heterogeneity.
- Conditions
- NET, Radionucleide Therapy, Contrast Enhanced Ultrasound
- Trial name
- DCEUS-PRRT (NCT07319416)
- Testing
- Vuebox
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Prospective study to obtain fresh tumor biopsies and three blood samples from patients with a confirmed histological or cytological diagnosis of well-differentiated neuroendocrine tumors (NETs) or well-differentiated pancreatic…
- Trial name
- NET-SEQ (NCT02586844)
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Neuroendocrine Tumors
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine…
- Trial name
- NCT05268952
- Testing
- Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
- Where
- 3 sites in Belgium, Cyprus
- Volunteers
- 100 people
- Sponsor
- University Hospital, Antwerp
Neuroendocrine Tumors, Neoplasm Metastasis
DEBOXA for Inoperable NET Liver Metastases
A prospective clinical trial to study the safety and effectiveness of Transcatheter Artery Chemotherapy and Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin (DEBOXA) in treating patients who have…
- Conditions
- Neuroendocrine Tumors, Neoplasm Metastasis, Liver
- Trial name
- NCT03881306
- Testing
- D-TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiangya Hospital of Central South University
Advanced/Metastatic Neuroendocrine Tumors
Pazopanib as Single Agent in Advanced NETs
The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R.
- Trial name
- NCT01280201
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH